Franceschini Gianluca, Di Leone Alba, Terribile Daniela, Sanchez Martin Alessandro, Masetti Riccardo
Ann Ital Chir. 2019;90:1-2.
Aim of this paper is to allows to analyze a topic of great relevance and media interest such as the role of prophylactic mastectomy in healthy women with BRCA mutation proposing to the surgeons some useful informations for decision-making. Less than 15% of all breast cancers are associated with germline genetic mutations. The majority of hereditary breast tumors are due to mutations in BRCA1 and BRCA2 genes that are responsible for only one third of hereditary cases. The risk estimates are extremely heterogeneous with a mean cumulative lifetime breast cancer risk of approximately 72% in BRCA1 and 69% in BRCA2 by age 80. The breast cancer is often bilateral and multicentric in BRCA mutation carriers. BRCA1 carriers have earlier-onset disease, particularly before age 50 and are more likely to develop aggressive triple-negative breast cancer than BRCA2 carriers or those who are BRCA mutation negative 1. Multiple strategies are effective in managing the risk of breast cancer in these women, including surveillance, chemoprevention, bilateral salpingo-oophorectomy and risk-reducing mastectomy. More intensive surveillance, including annual mammography and breast magnetic resonance imaging screening (commonly alternated every six months) beginning at age 25 or individualized based upon the earliest age of onset in the family, have significantly improved early detection of breast cancer among patients with deleterious BRCA mutations 1. The risk-reducing benefit of chemoprevention is not as well defined; chemopreventive strategies to reduce the risk of breast cancer have focused exclusively on prevention in high-risk women and involve the use of selective estrogen receptor modulators (SERMs) and aromatase inhibitors for breast cancer prevention. Only limited data are available regarding the preventive benefit of tamoxifene in BRCA mutations carriers 1. Risk-reducing bilateral salpingo-oophorectomy is recommended for BRCA mutation carriers by 35 to 40 or when childbearing is completed, or individualized based on age of onset of ovarian cancer in the family; bilateral salpingo-oophorectomy decreases the risk of both breast cancer and ovarian cancer in BRCA1 and BRCA2 mutation carriers and has also been associated with reduced all cause, breast cancer-specific, and ovarian cancer- specific mortality; risk-reducing bilateral salpingooophorectomy seems to offer an approximate 50% relative reduction in breast cancer risk 1. Prophylactic mastectomy provides the greatest reduction in risk of breast cancer development. In both retrospective and prospective observational studies, bilateral prophylactic mastectomy decreases the incidence of breast cancer by 90 percent or more in patients with BRCA mutation; it also is able to determine a variable gain in life expectancy compared to radiological surveillance; besides risk-reducing mastectomy allows to contain the strong anxiety and the fear of getting sick that often compromise the quality of life of BRCA mutation carriers 2. Prophylactic mastectomy could be technically performed in different ways. However, regarding the surgical technique, on the basis of current evidence, the gold standard seems to be represented by nipple-sparing mastectomy which, thanks to the preservation of the skin envelope and the nipple-areola complex, is able to optimize the oncological and aesthetic results. Nipple-sparing mastectomy provides superior cosmetic results. This procedure is usually performed through an inframmamary or radial or axillary incision where the skin is carefully dissected off the breast until all anatomic boundaries of the breast are reached and the gland in its entirety is excised. This technique does not seem to compromise the oncological/preventive efficacy compared to other types of mastectomy. In a multi-institution review of prophylactic 346 BRCA carriers undergoing either bilateral mastectomy or contralateral mastectomy with nipple- areola sparing there were no cases of breast cancer, whereas, based on models, 22 would have been expected 3. However nipple-sparing mastectomy must be carried out with technical skill and maximum attention not to leave macroscopic residues of mammary gland in particular in the axillary extension, peripheral extremities of the gland and the nipple-areola complex; it is necessary to perform an accurate dissection and a meticulous preparation of the skin flaps and of the areola-nipple complex which must be reasonably thin without however compromising its vitality. Whenever the patients opt to proceed with bilateral prophylactic mastectomy, an accurate preoperative radiological study should always be performed with mammography, ultrasound and magnetic resonance imaging to rule out the presence of suspicious breast lesions and minimize the risk of occult carcinomas by definitive histological examination. In the absence of contraindications, all patients should be candidates for breast reconstruction in order to minimize the negative physical and psychological impact of the mastectomy; the breast reconstruction should preferably be immediate, performed at the same time of the prophylactic mastectomy, by a team of dedicated plastic surgeons, or with permanent prosthesis or autologous tissues; the choice of the most appropriate reconstructive technique depends on various factors such as the physical/anatomical structure of the woman, the morphology/ degree of breast ptosis, the comorbidities but also the patient's wishes and preferences 1. However, in the discussion on the possibility of carrying out a prophylactic mastectomy, it is always necessary to consider a series of issues related to this procedure: - the possible oncological failure because risk-reducing mastectomy does not completely eliminate the risk of developing breast cancer; there is always a residual risk of about 5% to be related to the possible presence of residual glandular tissue or ectopic breast tissue 2; - the surgical morbidity with overall complication rates of 15-20% such as ischemia of the skin and/or of the areola-nipple complex, haematomas, infections, implant failure, partial/total autologous flap loss; in a considerable percentage of cases there is also the need to resort after the prophylactic mastectomy to further aesthetic/ plastic procedures to correct some imperfections or repair surgical complications 3-5; - the presence of sequelae such as the loss of sensitivity of the areola-nipple complex, possible paresthesias, painful sensations and the need for re-adaptation to a different body image 2; - the possible body image issues due to many factors, such as self-consciousness, feeling less sexually attractive and dissatisfaction with the scars 2,3. In addition to these issues we must add that most of the studies that show a gain in life expectancy thanks to prophylactic mastectomy, are based only on mathematical models and that the few prospective cohort studies often do not show a statistically significant improvement in terms of survival among women undergoing MP and intensive radiological surveillance 1,2. Therefore in consideration of the benefits but also of the problems that the prophylactic mastectomy involves, all the international guidelines highlight that this procedure must be considered, must be discussed with healthy BRCA women, however without giving an absolute recommendation to perform it 1. This discussion must take place, case by case, in specialized breast centers with a dedicated risk team. A personalized multidisciplinary path should guarantee an accurate genetic and clinical counselling, adequate psychological support and detailed information about all alternative risk management strategies. Clinical decision-making about strategies to pursue for breast cancer risk reduction should involve a tradeoff between life expectancy and quality of life. However if the patient and the medical team opt to proceed with prophylactic surgery, the cumulative evidence to date supports nipple sparing mastectomy with immediate reconstruction as an appropriate risk-reducing procedure to optimize the oncological and aesthetic results and improve quality of life.
本文旨在分析一个极具相关性且受媒体关注的话题,即预防性乳房切除术在携带BRCA突变的健康女性中的作用,为外科医生提供一些有用的决策信息。所有乳腺癌中,不到15%与种系基因突变相关。大多数遗传性乳腺肿瘤是由BRCA1和BRCA2基因的突变引起的,这些突变仅占遗传性病例的三分之一。风险估计差异极大,到80岁时,BRCA1携带者的平均累积终身乳腺癌风险约为72%,BRCA2携带者为69%。携带BRCA突变的患者,乳腺癌常为双侧且多中心性。BRCA1携带者发病更早,尤其是在50岁之前,且比BRCA2携带者或BRCA突变阴性者更易患侵袭性三阴性乳腺癌。多种策略可有效管理这些女性的乳腺癌风险,包括监测、化学预防、双侧输卵管卵巢切除术和降低风险的乳房切除术。更密集的监测,包括从25岁开始每年进行乳房X线摄影和乳房磁共振成像筛查(通常每六个月交替进行),或根据家族中最早发病年龄进行个体化筛查,已显著提高了有害BRCA突变患者乳腺癌的早期检测率。化学预防降低风险的益处尚不明确;降低乳腺癌风险的化学预防策略仅专注于高危女性的预防,涉及使用选择性雌激素受体调节剂(SERM)和芳香化酶抑制剂预防乳腺癌。关于他莫昔芬在BRCA突变携带者中的预防益处,仅有有限的数据。对于BRCA突变携带者,建议在35至40岁或生育完成后进行降低风险的双侧输卵管卵巢切除术,或根据家族中卵巢癌发病年龄进行个体化手术;双侧输卵管卵巢切除术可降低BRCA1和BRCA2突变携带者患乳腺癌和卵巢癌的风险,还与全因死亡率、乳腺癌特异性死亡率和卵巢癌特异性死亡率降低相关;降低风险的双侧输卵管卵巢切除术似乎可使乳腺癌风险相对降低约50%。预防性乳房切除术能最大程度降低患乳腺癌的风险。在回顾性和前瞻性观察研究中,双侧预防性乳房切除术可使BRCA突变患者的乳腺癌发病率降低90%以上;与放射学监测相比,它还能在预期寿命方面带来不同程度的增加;此外,降低风险的乳房切除术可缓解强烈的焦虑和对患病的恐惧,这些常常会影响BRCA突变携带者的生活质量。预防性乳房切除术在技术上可采用不同方式进行。然而,就手术技术而言,根据目前的证据,金标准似乎是保留乳头的乳房切除术,由于保留了皮肤包膜和乳头乳晕复合体,该术式能够优化肿瘤学和美学效果。保留乳头的乳房切除术具有更好的美容效果。该手术通常通过乳房下皱襞、放射状或腋窝切口进行,在该过程中,需小心地将皮肤从乳房上剥离,直至到达乳房的所有解剖边界,然后完整切除腺体。与其他类型的乳房切除术相比,该技术似乎不会影响肿瘤学/预防效果。在一项对346例接受双侧乳房切除术或保留乳头乳晕的对侧乳房切除术的BRCA携带者的多机构回顾中,未发现乳腺癌病例,而根据模型预测,预计会有22例。然而,进行保留乳头的乳房切除术必须具备技术技巧并格外小心,尤其要注意在腋窝延伸处、腺体周边以及乳头乳晕复合体处不留乳腺的宏观残留物;必须准确解剖并精心准备皮瓣和乳晕乳头复合体,其厚度应合理变薄,但不能影响其活力。每当患者选择进行双侧预防性乳房切除术时,术前应始终进行精确的放射学检查,包括乳房X线摄影、超声和磁共振成像,以排除可疑的乳腺病变,并通过确定性组织学检查将隐匿性癌的风险降至最低。在没有禁忌证的情况下,所有患者都应成为乳房重建的候选人,以尽量减少乳房切除术对身体和心理的负面影响;乳房重建最好在预防性乳房切除术的同时立即进行,由专业的整形外科团队进行,可使用永久性假体或自体组织;选择最合适的重建技术取决于多种因素,如女性的身体/解剖结构、乳房下垂的形态/程度、合并症,以及患者的意愿和偏好。然而,在讨论进行预防性乳房切除术的可能性时,始终有必要考虑与该手术相关的一系列问题: - 可能存在肿瘤学失败,因为降低风险的乳房切除术并不能完全消除患乳腺癌的风险;由于可能存在残留的腺体组织或异位乳腺组织,则始终存在约5%的残余风险; - 手术并发症,总体并发症发生率为15 - 20%,如皮肤和/或乳晕乳头复合体缺血、血肿、感染、植入物失败、部分/全部自体皮瓣丢失;在相当比例的病例中,预防性乳房切除术后还需要进行进一步的美容/整形手术,以纠正一些瑕疵或修复手术并发症; - 存在后遗症,如乳晕乳头复合体感觉丧失、可能的感觉异常、疼痛感觉以及需要重新适应不同的身体形象; - 由于多种因素,如自我意识、感觉性吸引力下降以及对疤痕的不满,可能出现身体形象问题。除了这些问题,我们还必须补充一点,大多数显示预防性乳房切除术可延长预期寿命的研究仅基于数学模型,而少数前瞻性队列研究往往未显示接受预防性乳房切除术和强化放射学监测的女性在生存方面有统计学上的显著改善。因此,考虑到预防性乳房切除术的益处以及所涉及的问题,所有国际指南都强调,必须考虑该手术,必须与健康的BRCA女性进行讨论,但不给出绝对的实施建议。这种讨论应逐案在设有专门风险团队的专业乳腺中心进行。个性化的多学科路径应确保准确的遗传和临床咨询、充分的心理支持以及关于所有替代风险管理策略的详细信息。关于降低乳腺癌风险策略的临床决策应在预期寿命和生活质量之间进行权衡。然而,如果患者和医疗团队选择进行预防性手术,迄今为止的累积证据支持保留乳头的乳房切除术并立即进行重建,这是一种合适的降低风险的手术,可优化肿瘤学和美学效果并提高生活质量。